Syngene International has approved the voluntary liquidation of its wholly-owned subsidiary, Syngene Manufacturing Solutions Limited (SMSL). The decision was taken during a board meeting held on May 18, 2026. The subsidiary, which is not a material subsidiary, had ceased business operations, prompting the move to liquidate it as a solvent entity under the Insolvency and Bankruptcy Code, 2016.

The board determined that the liquidation would not affect the company's business operations and would have no material impact on its consolidated financials. The closure of SMSL is expected to be completed in accordance with the timelines stipulated under the relevant regulations, subject to shareholder and necessary governmental approvals.

Financial Details of SMSL

For the financial year ended March 31, 2026, SMSL reported nil turnover and a net worth of ₹93,97,513, which represented 0.02% of the company's total net worth. The following table outlines the financial contributions of the subsidiary:

*For the financial year ended March 31, 2026

Regulatory and Approval Process

The voluntary liquidation process will adhere to the Insolvency and Bankruptcy Board of India (Voluntary Liquidation Process) Regulations, 2017. The company has stated that the transaction does not fall under related party transactions and is not part of any slump sale or scheme of arrangement. The completion of the liquidation is contingent upon approvals from SMSL shareholders and other statutory authorities, if required.

The board meeting, which commenced at 21:05 IST and concluded at 22:00 IST, also reviewed other regulatory disclosures. The information regarding the liquidation has been made available on the company's website.

Syngene International announced its audited financial results for the quarter and year ended March 31, 2026, following a Board meeting held on April 29, 2026. The company reported mixed quarterly performance with revenue growth but declining profitability compared to the previous year. The audited consolidated financial results were published in newspapers on May 1, 2026, under Regulation 33 of SEBI Listing Regulations. Subsequently, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company also intimated exchanges on May 4, 2026, about the availability of the Q4 FY2026 Earnings Call transcript on its website, following the earnings call held on April 30, 2026.

Quarterly Performance Analysis

For the fourth quarter ended March 31, 2026, Syngene International demonstrated contrasting performance metrics. While the company achieved revenue growth, profitability indicators showed a decline compared to the same period last year.

Basic earnings per share for Q4 FY26 stood at Rs 3.68 compared to Rs 4.56 in Q4 FY25, while diluted EPS was Rs 3.67 against Rs 4.56 in the previous year.

Annual Financial Performance

The standalone revenue from operations for FY26 reached Rs 34,238 million, while consolidated revenue was Rs 37,387 million compared to Rs 36,424 million in the previous year. Profit for the year stood at Rs 3,049 million on a standalone basis and Rs 3,167 million on a consolidated basis. The table below provides a comprehensive view of the full-year financial metrics across both standalone and consolidated bases.

Operating Highlights and Key Management Changes

The company commenced operations at the ADC discovery laboratory during Q4 FY26, establishing end-to-end ADC (Antibody-Drug Conjugate) capabilities from discovery to manufacturing. Quality & Regulatory achievements included completion of 14 audits during the quarter (FY total: 85) and GCP-NABL accreditation. The company was included in the S&P Global Sustainability Yearbook 2026, ranking in the top 10 life sciences companies and top 9% globally.

Key management changes were announced: Kiran Mazumdar-Shaw transitioned from Non-Executive Chairperson to Executive Chairperson effective April 1, 2026, for a five-year term. Siddharth Mittal was appointed Managing Director & Chief Executive Officer effective July 1, 2026, succeeding Peter Bains. Maninder Kapoor Puri was appointed Chief Human Resources Officer and Abhijit Zutshi was appointed Chief Commercial Officer, both effective May 1, 2026.

Dividend Declaration and Board Decisions

The Board of Directors recommended a final dividend of Rs 1.25 per equity share of Rs 10 each for the financial year 2025-26. The record date has been fixed as Friday, June 26, 2026, for determining eligibility for dividend payment. The Board approved the appointment of M/s S. R. Batliboi & Associates LLP as statutory auditors for five years and convening of the 33rd Annual General Meeting on Wednesday, July 29, 2026.

Earnings Call Transcript and Regulatory Compliance

Following the earnings call held on April 30, 2026, Syngene International filed an intimation with BSE Limited and the National Stock Exchange of India Limited on May 4, 2026, under Regulation 30 of SEBI Listing Regulations, providing access to the Q4 FY2026 Earnings Call transcript. The transcript is available on the company's website. The audited financial results were officially published in Financial Express (All India Edition) and Vijayavani (Bengaluru Edition) on May 1, 2026. The financial statements were reviewed by the Audit Committee on April 28, 2026, and approved by the Board of Directors on April 29, 2026. The statutory auditor reports are unqualified, and the statements were prepared in accordance with Indian Accounting Standards prescribed under the Companies Act, 2013.